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SUMMARY – Ventilator-associated pneumonia (VAP) is the most common infection among 
intensive care unit (ICU) patients. The aim of the present study was to evaluate the impact of tra-
cheotomy on VAP clinical course. The study was conducted in a 15-bed Surgical and Neurosurgical 
ICU, Department of Anesthesiology and Intensive Care, Sestre milosrdnice University Hospital 
Center in Zagreb, Croatia. All patients developing VAP during ICU stay were eligible for the study. 
In VAP patients not tracheotomized during ICU stay, the mortality rate was approximately two 
times higher as compared with patients tracheotomized either before or after VAP onset (crude 
risk ratio 1.83, 95% confidence interval (95% CI) 1.15-2.91, p=0.01; crude odds ratio 3.47, 95% CI 
1.52-7.94; p=0.003). In the surviving VAP patients, the duration of mechanical ventilation before 
VAP onset was higher in the “T before VAP” group as compared with the “no T before VAP” gro-
up (8, 6-10 vs. 3, 2-5; p<0.001), but the number of post-VAP days on mechanical ventilation was 
shorter in “T before VAP” patients than in “no T before VAP” patients (0, 0-1 vs. 4, 3-9; p<0.001). 
The duration of mechanical ventilation after VAP onset in the “T after VAP” group was longer as 
compared with the “T before VAP” group (4, 3-12 vs. 0, 0-1; p<0.001). The present study indicated 
tracheotomy to be associated with a reduced duration of mechanical ventilation after VAP onset, but 
only if patients were tracheotomized at the moment of VAP onset. 
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Introduction
Ventilator-associated pneumonia (VAP) is the 
most common infection among intensive care unit 
(ICU) patients1,2. VAP is defined as a type of nosoco-
mial pneumonia occurring more than 48 hours after 
intubation and mechanical ventilation. VAP occurs 
in 8%-28% of all intubated patients1. Generally, sur-
gical ICUs have higher VAP rates as compared with 
non-surgical ones3. VAP is the leading cause of ICU 
mortality, with the reported mortality rates ranging 
from 24% to 76%1. Microorganisms most commonly 
responsible for VAP onset are Pseudomonas aerugi-
nosa, Staphylococcus aureus and Enterobacteriaceae, but 
causative agents widely differ depending on the ICU 
patient population, duration of ICU stay, VAP on-
set point, underlying diseases and hospital settings1. 
A number of risk factors may favor VAP onset, the 
most commonly reported among them being dura-
tion of mechanical ventilation (MV), enteral feeding, 
number of re-intubations, severity of illness (Acute 
Physiology and Chronic Health Evaluation II score, 
APACHE II score), underlying pulmonary disease, 
supine body position, depressed consciousness, prior 
exposure to antibiotic therapy, tracheotomy, etc.2. The 
role of tracheotomy in VAP development remains 
controversial. While tracheotomy may protect against 
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VAP because it facilitates bronchial toilette, reduces 
longstanding epithelial injury and improves patient 
mobility as compared with endotracheal intubation4, 
it may, at the same time, increase the risk of VAP on-
set because of the direct injury to the airways and pos-
sible insertion of bacteria during the procedure5. The 
impact of tracheotomy on the development of VAP is 
not clearly defined. Some studies found decreases in 
VAP rates in patients having tracheotomy6-12, others 
have reported tracheotomy to be a risk factor favor-
ing VAP onset13-20, while some could not demonstrate 
any VAP-related impact whatsoever21-24. Because of 
the conflicting literature data, there is currently no 
consensus on tracheotomy as either a VAP-protective 
or VAP-causative factor5. The article by Vello et al.5, 
which reviews the literature that explores the relation-
ship between tracheotomy and VAP, claims that ex-
plicit data on tracheotomy-VAP timeline can be found 
in not more than 4 studies8,13,24,25. 
The aim of the present study was to evaluate the 
impact of tracheotomy on the clinical course of VAP, 
as well as to assess the risk factors associated with le-
thal VAP outcomes.
Patients and Methods
The study was conducted in a 15-bed Surgical and 
Neurosurgical ICU, Department of Anesthesiology 
and Intensive Care, Sestre milosrdnice University 
Hospital Center, Zagreb, Croatia. The study was ap-
proved by the Hospital′s Board of Ethics (E.P. num-
ber: 35-1/09). Retrospective data were collected from 
September 2009 to March 2013. Because of the ret-
rospective and observational nature of the study, an 
informed consent was unnecessary. 
All ICU patients that developed VAP during the 
study period were eligible for the study. Patients were 
divided into two groups based on VAP onset in rela-
tion to tracheotomy time-point (“no T before VAP” 
and “T before VAP”). The study arm “not tracheoto-
mized before VAP” was divided into “never tracheoto-
mized” (“no T after VAP”) and “tracheotomized after 
VAP onset” (“T after VAP”) sub-arms. 
Reasons for ICU admission were medical, trauma 
without surgery or surgery. As for clinical diagnosis, 
VAP was established on the Clinical Pulmonary In-
fection Score (CPIS) based on six clinical assessments, 
each worth zero to two points26. A score of more than 
six was considered suggestive of VAP. The CPIS score 
was calculated when there was clinical suspicion of 
VAP (presence of new or progressive infiltration on 
chest radiography and presence of at least two of the 
following criteria: fever, leukocytosis and purulent 
tracheal secretion). Only the first VAP episode was 
evaluated. Quantitative culture of endotracheal aspi-
rate (ETA) was performed so as to identify the VAP 
pathogens. A pathogen isolated at a concentration of 
more than 105 CFU/mL was considered causative of 
VAP. Endotracheal aspirate sample with more than 
10 squamous epithelial cells per visual field represents 
an invalid sample27. Purulent sputum is defined as 
secretions from the lungs that contain more than 25 
neutrophils per visual field. 
Patients were tracheotomized surgically or percu-
taneously. Surgical tracheotomies were performed in 
the operating room by otolaryngologists. Percutane-
ous tracheotomies were performed at patient bedside 
by ICU physicians using the Griggs method. 
The exclusion criteria were pneumonia prior to MV 
or within 48 hours following MV initiation, trache-
otomy performed before ICU admission, emergency 
tracheotomy, and age below 18. 
All patients were fed enterally using a nasogastric 
tube (in most patients starting from the second day of 
ICU stay), received systemic stress ulcer prophylaxis 
(ranitidine or proton pump inhibitors) and were kept 
in a semi-recumbent position during their ICU stay.
The inter-group comparison was based on the pa-
tient status at ICU admission and during ICU stay, 
characteristics of VAP and clinical outcomes. 
Statistical analysis
Since continuous variables were not distributed 
normally, the differences between the groups were an-
alyzed using the Kruskal-Wallis ANOVA followed by 
the post hoc Mann-Whitney U-test (with a modified 
Bonferroni correction) whenever the ANOVA yielded 
a statistically significant result. As for categorical vari-
ables, the inter-group differences were analyzed using 
the Pearson’s χ2 or the Fisher test (with Bonferroni-
Sidak correction) whenever the overall results of the 
above tests were statistically significant.
The risk of mortality was analyzed as crude risk 
and odds ratio, and in the multiple linear logistic re-
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gression models, controlled for potentially relevant 
confounders, i.e. APACHE II score at admission, 
Simplified Acute Physiology Score II (SAPS II) at 
admission, tracheotomy, total duration of MV, comor-
bidities (malignant disease, chronic cardiac disease, 
and diabetes mellitus), type of surgical patients and 
use of corticosteroids. In order to maintain the recom-
mended ratio of the number of predictors vs. number 
of study subjects28, as predictors in the models were 
chosen variables found to statistically significantly dif-
fer between tracheotomized and non-tracheotomized 
patients (SAPS II at admission, APACHE II score 
at admission, diabetes mellitus, type of surgical pa-
tients) or to be significantly related to studied outcome 
on univariate analyses (tracheotomy, total duration of 
MV, malignant disease, chronic cardiac disease and 
use of corticosteroids), while not being inter-correlat-
ed with other predictors. 
Statistical analysis was performed using Stata/SE 
11.2 for Windows (StataCorp LP, USA), at the 0.05 
level of significance. 
Results
During the study period, 5071 adult patients were 
admitted to our ICU. Four hundred and fifty-three 
(8.9%) of these patients were intubated and mechani-
cally ventilated for more than 48 hours, 178 (39%) of 
these tracheotomized during their ICU stay. VAP de-
veloped in 113 (25%) patients, 98 of these not tracheot-
omized before VAP onset (“no T before VAP”) and 15 
tracheotomized before VAP onset (“T before VAP”). 
Table 1. Characteristics of VAP patients according to tracheotomy (T) status at ICU admission 
No T before VAP T before VAP p-value
No T after VAP T after VAP
Number of patients 36 62 15
Men 20 (56) 44 (71) 5 (53) 0.207
Age (years) 72 (60-78) 67 (48-76) 70 (58-80) 0.282
Smokers 7 (19) 14 (23) 2 (13) 0.717
SAPS II 31 (27-39) 41 (27-50) 41 (35-58) 0.024
APACHE II score 12 (9-16) 16 (12-20) 17 (12-20) 0.024
Comorbidity
Diabetes mellitus 4 (11) 9 (15) 6 (40) 0.033
Malignant disease 7 (19) 8 (19) 0 0.174
COPD 6 (17) 7 (11) 3 (20) 0.598
Chronic cardiac disease 11 (31) 13 (21) 4 (27) 0.561
Kidney failure 4 (11) 2 (3) 2 (13) 0.204
Hypertension 19 (53) 25 (40) 8 (53) 0.408
Alcoholism 3 (8) 10 (16) 2 (13) 0.548
Main reason for ICU admission
Medical∗ 0 3 (5) 0
0.234Trauma without surgery 0 5 (8) 0
Surgery 36 (100) 54 (87) 15 (100)
Type of surgical patients
General surgical† 25 (69) 19 (35) 4 (27)
0.002
Neurosurgical 11 (31) 35 (65) 11 (73)
Results are presented as median (25th-75th interquartile range) or as number (%); VAP = ventilator-associated pneumonia; T = tracheotomy; 
ICU = intensive care unit; SAPS II = Simplified Acute Physiology Score II; APACHE II score = Acute Physiology and Chronic Health 
Evaluation II score; COPD = chronic obstructive pulmonary disease; *acute respiratory failure, sepsis, state after resuscitation; †neck, thorax, 
abdomen
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Characteristics of VAP patients established at admission 
and during ICU stay
Table 1 shows the characteristics of VAP patients 
established at ICU admission. Patient groups did not 
differ significantly according to gender, age, smoking 
habit, and prevalence of the majority of comorbidities, 
with the exception of diabetes mellitus. Diabetes mel-
litus was most prevalent in the “T before VAP” group. 
SAPS II and APACHE II scores (taken during the 
first 24 hours following ICU admission) were lower 
in the “no T after VAP” as compared to the “T after 
VAP” and the “T before VAP” groups. Reasons for 
ICU admission did not differ significantly between 
the groups (Table 1). During study period there were 
105 (93%) surgical patients: 48 (46%) general surgical 
(including surgery of neck, thorax and abdomen) and 
57 (54%) neurosurgical (including surgery of head) 
patients. The type of surgical patients significantly 
differed between the groups: surgery of neck, thorax 
and abdomen as the grounds for ICU admission pre-
vailed in not tracheotomized patients (25/36, 69%), 
while neurosurgery-related ICU admissions were 
most often seen in tracheotomized patients (46/77, 
60%) (p=0.002).
Table 2 shows the characteristics of VAP patients 
observed during the ICU stay. Reasons for MV and 
performing tracheotomy are shown in Table 2. Dura-
tion of MV before VAP and the number of days at 
ICU before VAP were the longest in the “T before 
VAP” group. The groups did not differ significantly in 
Table 2. Characteristics of VAP patients according to tracheotomy (T) status during ICU stay
No T before VAP T before VAP p-value
No T after VAP T after VAP
Number of patients 36 62 15
Reason for MV
Respiratory* 26 (72) 35 (56) 8 (53)
0.163Neurological† 6 (17) 12 (20) 1 (7)
Sedation 4 (11) 15 (24) 6 (40)
Number of days of MV before VAP 7 (3-11) 3 (2-5) 9 (6-14) <0.001
Number of days at ICU before VAP 5 (4-7) 5 (4-9) 12 (10-24) <0.001
Number of reintubations 2 (0-3) 1 (0-2) 0 (0-2) 0.098
Reason for T
Respiratory‡ - 31 (50) 6 (40)
0.487
Neurologic§ - 31 (50) 9 (60)
Number of days of MV before T - 6 (4-9) 7 (4-7) 0.777
Number of days at ICU before T - 9 (7-14) 8 (6-11) 0.242
Number of days from T to VAP - - 6 (3-13)
Number of patients treated with anti-
biotics 36 (100) 62 (100) 15 (100) 1.000
Number of antibiotics before VAP 2 (0-3) 1 (0-2) 3 (2-5) 0.012
Number of antibiotics before T - 2 (1-3) 2 (1-3) 0.919
Total number of antibiotics 3 (2-5) 3 (2-5) 4 (2-8) 0.738
Number of patients treated with corti-
costeroids 8 (22) 17 (27) 2 (13) 0.473
Number of sedated patients 7 (19) 26 (42) 9 (60) 0.012
Results are presented as median (25th-75th interquartile range, or as number (%); VAP = ventilator-associated pneumonia; ICU = intensive 
care unit; T = tracheotomy, MV = mechanical ventilation; *acute respiratory failure, neuromuscular weakness, acute respiratory distress 
syndrome; †Glasgow Coma Score (GCS) lower than 9; ‡predicted long MV due to trauma or disease of the lung (>10 days), weaning dif-
ficulties, neuromuscular weakness/need for frequent suctioning (>10-12 times daily); §GCS lower than 9
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the reason for MV or tracheotomy, number of reintu-
bations, number of days of MV or number of ICU days 
prior to tracheotomy, representation of corticosteroid-
treated and antibiotic-treated patients. Patient groups 
did not differ significantly in total number of antibiot-
ics and number of antibiotics before tracheotomy, but 
there was a higher number of antibiotics before VAP 
in “T before VAP” group as compared to the “no T 
before VAP” group. Also, during study period there 
was more sedation in “T before VAP” group. 
Characteristics of VAP
Significant differences in CPIS scores between the 
groups failed to be found. The representation of all 
parameters of CPIS did not significantly differ be-
tween the groups (Table 3). In all patients with valid 
ETA (<10 squamous epithelial cells per visual field), 
the infection was polymicrobial. Eleven patients 
were excluded from final analysis of the etiology of 
VAP because they had growth of bacteria below the 
concentration of 105 CFU/mL. So, final analysis of 
bacterial etiology of VAP included 93 patients/ETA 
samples with 147 isolated bacterial species. In all pa-
tient groups, the most common causative agents were 
gram-negative bacteria (Table 4). Pseudomonas aerugi-
nosa was the most prevalent gram-negative bacterium 
in all groups. Other frequently isolated gram-negative 
bacteria were Acinetobacter species, Enterobacter spe-
cies and Escherichia coli in the “no T after VAP” group, 
Escherichia coli, Haemophilus influenzae, Acinetobacter 
species and Escherichia coli in the “T after VAP” 
group, and Acinetobacter species, Escherichia coli and 
Haemophilus influenzae in the “T before VAP” group. 
Among gram-positive bacteria, the most prevalent 
species seen across the study groups was Staphylococcus 
aureus (in up to 38% of analyzed samples). Methicil-
lin-resistant Staphylococcus aureus (MRSA) was iso-
lated in 15 of 31 (48.4%) cases of Staphylococcus aureus 
infection. MRSA was isolated in 6 out of 30 (20%) 
ETA samples in the “no T after VAP” group, 6 out 
Table 3. Characteristics of VAP according to tracheotomy (T) status 
No T before VAP T before VAP p-value
No T after VAP T after VAP
Number of patients 36 62 15
CPIS score 7 (7-9) 8 (7-9) 8 (7-9)
Temperature (°C) 37.5 (37.0-38.7) 38.0 (37.2-38.6) 38.5 (37.2-39.3) 0.425
Leukocyte number (per mm3) 12 (9-16) 14 (10-19) 12 (10-18) 0.451
Tracheal secretion 
Rare 3 (8) 3 (5) 0
0.552Abundant 8 (22) 12 (19) 5 (33)
Abundant + purulent* 25 (69) 47 (76) 10 (67)
PaO2/fiO2 (mm Hg) 209 (168-256) 195 (157-298) 170 (114-217) 0.238
Chest radiograph 
No infiltrate 2 (6) 4 (6) 1 (8)
0.345Diffuse infiltrates 10 (28) 11 (18) 6 (40)
Localized infiltrate 24 (67) 47 (76) 8 (53)
ETA
Number of valid ETA† 33 (92) 56 (93) 15 (100) 0.529
Number of valid positive ETA‡ 30 (83) 50 (81) 13 (87) 0.979
Polymicrobial ETA 33 (100) 56 (100) 15 (100) 0.163
Results are presented as median (25th-75th interquartile range) or as number (%); VAP = ventilator-associated pneumonia; T = tracheotomy, 
ETA = endotracheobronchial aspirate; CPIS = Clinical Pulmonary Infection Score; *contains more than 25 neutrophils per visual field; 
†ETA with <10 squamous epithelial cells per visual field; ‡ETA with <10 squamous epithelial cells per visual field and pathogen isolated at 
a  concentration of more than 105 CFU/mL
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of 50 (12%) ETA samples in the “T after VAP” group 
and 3 out of 13 (23%) ETA samples in the “T before 
VAP” group (p=0.490). Among all bacteria, the most 
prevalent bacterium was Pseudomonas aeruginosa in 
the “no T after VAP” group (47% vs. 20% vs. 31%; 
p=0.042), while in the other two groups, the most 
prevalent bacterium was Staphylococcus aureus (found 
in 38% of analyzed ETA samples), but the difference 
did not reach statistical significance (p=0.369).
Outcomes of study patients
In VAP patients not tracheotomized during ICU 
stay, mortality rates were approximately two-times 
higher as compared with patients tracheotomized ei-
ther before or after VAP onset (crude risk ratio 1.83, 
95% confidence interval (95% CI) 1.15-2.91, p=0.01; 
crude odds ratio 3.47, 95% CI 1.52-7.94; p=0.003) 
(Table 5). This result was confirmed by multiple linear 
logistic regression analysis adjusted for tracheotomy, 
comorbidities (malignant disease, chronic cardiac 
disease), duration of MV and use of corticosteroids 
(Pmodel<0.001, Pseudo R2=0.193). The model revealed 
the odds ratio for lethal outcome to be 0.19 (95% CI 
0.07-0.51, p=0.001) in tracheotomized versus non-
tracheotomized VAP patients (regardless of tracheot-
omy timing). Other significant predictors, all of them 
correlated to lethal outcomes, were duration of MV 
(OR 1.00, 95% CI 1.00-1.1, p=0.029) and use of cor-
ticosteroids (OR 0.3, 95% CI 0.1-0.8, p=0.019). In the 
surviving VAP patients, the length of ICU stay be-
fore VAP was twice shorter in the “no T before VAP” 
group as compared with the “T before VAP” patients. 
The number of days from VAP to ICU release was 
higher in the “T after VAP” group than in the non-
tracheotomized and “T before VAP” patients. The 
number of pre-VAP days on MV was twice higher in 
Table 4. Bacterial species isolated from ETA in VAP patients
No T before VAP T before VAP p-value
No T after VAP T after VAP
Number of ETA samples 30 50 13
Total number of bacteria 50 76 21
Gram-negative bacteria 42 (84) 53 (70) 15 (71)
Moraxella catarrhalis 0 2 (4) 0 0.415
Haemophilus influenzae 1 (3) 10 (20) 2 (15) 0.113
Pseudomonas aeruginosa 14 (47) 10 (20) 4 (31) 0.042
Acinetobacter species  8 (27) 8 (16) 4 (31) 0.362
Stenotrophomonas malthophilia 2 (7) 0 0 0.117
Escherichia coli 5 (17) 8 (16) 3 (23) 0.830
Klebsiella species 4 (13) 5 (10) 0 0.395
Enterobacter species 6 (20) 5 (10) 1 (8) 0.362
Proteus mirabilis 0 2 (4) 0 0.415
Serratia species 2 (7) 1 (2) 0 0.404
Citrobacter species 0 2 (4) 0 0.415
Unspecified gram-negative bacteria 0 0 1 (8) 0.044
Gram-positive bacteria 8 (16) 23 (30) 6 (29)
Staphylococcus aureus 7 (23) 19 (38) 5 (38) 0.369
Streptococcus pneumoniae 1 (3) 3 (6) 0 0.605
β-hemolytic Streptococcus group B 0 1 (2) 0 0.647
Unspecified gram-positive bacteria 0 0 1 (8) 0.044
Results are presented as the number of bacterial species isolates (% out of the number of ETA samples); VAP = ventilator-associated pneu-
monia; T = tracheotomy; ETA = endotracheobronchial aspirate
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the patients tracheotomized before VAP onset than 
in the “no T before VAP” patients. The number of 
post-VAP days on MV was higher in the “no T before 
VAP” group as compared with the “T before VAP” 
group. In the “T before VAP” group, the number of 
post-VAP days on MV was 0 (0-1). Other endpoints 
analyzed in surviving patients, i.e. total length of ICU 
stay, number of ICU days before tracheotomy, num-
ber of days elapsed from tracheotomy to ICU release, 
total duration of MV, number of pre- and post-T days 
on MV and SAPS II at release, did not differ between 
the groups.
Discussion
Ventilator-associated pneumonia mortality rates 
range from 24% to 50%, and can reach 76% in certain 
specific settings or when VAP is caused by high-risk 
pathogens1. Some studies suggest the mortality to be 
increased in tracheotomized patients25. According to 
our data, in VAP patients not tracheotomized during 
ICU stay, the mortality was approximately two-fold 
higher than in patients tracheotomized either before 
or after VAP onset. Other predictors positively cor-
related with lethal outcomes were duration of MV 
and use of corticosteroids, which is consistent with the 
results of many other studies3,13-15,29. Koleff et al. also 
found the mortality of patients receiving tracheotomy 
to be lower than the mortality of non-tracheotomized 
patients17. One large retrospective observational co-
hort study found tracheotomy to be associated with 
an improved in-hospital survival30. 
Data on the surviving patients showed that the to-
tal duration of MV and total length of ICU stay were 
the same in all groups. The duration of MV before 
VAP, as well as the length of ICU stay before VAP, 
were two times longer in the “T before VAP” group as 
compared with the “no T before VAP” group, but the 
mortality was the same as in the “ T after VAP” group 
or lower than in the “no T after VAP” group. It is also 
interesting to note that the duration of MV after VAP 
was shortest in the “T after VAP” group, suggesting 
that tracheotomy shortens the duration of MV after 
VAP and consequently yields better patient outcomes, 
but only if the procedure is performed prior to VAP 
onset. The ICU length of stay after VAP was longest 
in the “T after VAP” group, but probably only because 
tracheotomy in that group was done later than in the 
“T before VAP” group. 
During the study period, the incidence of VAP in 
our ICU was 25%. According to current literature, the 
incidence of VAP generally ranges from 8% to 28%1, 
but can be much higher, especially in surgical ICUs3. 
Table 5. Outcome of study patients
No T before VAP T before VAP p-value
No T after VAP T after VAP
Mortality 23 (64) 21 (34) 5 (33)
Surviving VAP patients 13 (36) 41 (66) 10 (67) 0.011
Length of ICU stay (days) 15 (11-20) 21 (14-36) 22 (16-28) 0.113
Number of days at ICU before VAP 5 (3-7) 5 (4-11) 11 (10-13) <0.001
Number of days at ICU before T - 10 (6-13) 8 (5-10) 0.152
Number of days from VAP to ICU release 10 (6-15) 14 (10-27) 9 (3-13) 0.033
Number of days from T to ICU release - 11 (6-16) 15 (9-19) 0.354
Total duration of MV (days) 7 (5-11) 9 (6-18) 8 (6-12) 0.747
Number of days of MV before VAP 3 (1-6) 4 (2-6) 8 (6-10) 0.001
Number of days of MV before T - 6 (4-9) 6 (4-7) 0.566
Number of days of MV after VAP 4 (3-7) 4 (3-12)  0 (0-1) 0.001
Number of days of MV after T - 2 (0-9) 2 (1-8) 0.853
SAPS II at release 21 (15-25) 26 (20-31) 23 (15-25) 0.231
Results are presented as median (25th-75th interquartile range) or as number (%); ICU = intensive care unit; VAP = ventilator-associated 
pneumonia; MV = mechanical ventilation; T = tracheotomy; SAPS II = Simplified Acute Physiology Score II
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Therefore, the high rate of VAP found in our surgical 
ICU is in line with these data. In our ICU patients, 
tracheotomy reduced the relative risk of VAP onset by 
67% (relative risk 0.33, 95% CI 0.20-0.56). Namely, 
in 453 ICU patients mechanically ventilated for >48 
h, VAP developed in 98 of 290 (34%) “non-T” patients 
and in only 15 of 163 (9%) “T” patients. The above-
stated relative risk of VAP onset, seen in our “T” and 
“non-T” ICU patients, represents a crude risk ratio, 
since data on the potential confounders in mechani-
cally ventilated patients who did not develop VAP 
during ICU stay were not collected at this point. 
According to the literature, the incidence of VAP 
among tracheotomized patients varies from 6% to 
26%9,31,32. However, many studies failed to specify the 
time elapsed between tracheotomy and VAP onset. 
Only a small number of studies explicitly state whether 
tracheotomy preceded VAP or followed it8,13,15,22,25,30. 
To that matter, the work of Nseir et al. even warns that 
the incidence of VAP after tracheotomy never got to 
be compared with the incidence before tracheotomy 
or the incidence in patients without tracheotomy8. 
Pawar et al. found that most VAP cases (88.9%) oc-
curred before tracheotomy, so that tracheotomy came 
as a result of VAP rather than posing a risk factor fa-
voring its development15. According to our data, the 
incidence of VAP among tracheotomized patients was 
68% (77/113), while the incidence of VAP among non-
tracheotomized patients was 32% (36/113), the time 
elapsed between tracheotomy and VAP onset hereby 
not being taken into consideration. But, if we take into 
account only the patients that developed VAP after T, 
the incidence of VAP among tracheotomized patients 
would drop to 13% (15/113) only. 
Lower SAPS II and APACHE II scores probably 
were the reasons why tracheotomy was not performed 
in the “no T after VAP” group. Despite lower SAPS 
II and APACHE II scores, the mortality among the 
non-tracheotomized patients was approximately two-
times higher as compared with the patients trache-
otomized either before or after VAP onset. Our data 
suggest that tracheotomy reduces mortality of VAP 
patients, even if performed following VAP onset. 
The main reason for ICU admission differed be-
tween the groups; the most prevalent reason in trache-
otomized patients was neurosurgery, probably because 
prolonged mechanical ventilation was to be expected. 
In non-tracheotomized VAP patients, on the other 
hand, the most prevalent ground for ICU admission 
was general surgery, probably because of respiratory 
problems not seen immediately after surgery, but in 
the later ICU stay course. 
A higher use of sedatives was recorded in trache-
otomized patients, especially in the “T before VAP” 
group; namely, since most of these patients were 
admitted to ICU due to neurotrauma, the severity 
of their injuries mandated intentional few-day seda-
tion. 
Approximately 58% of VAP-causing microorgan-
isms isolated within the frame of various studies were 
gram-negative bacteria, among which Pseudomonas 
aeruginosa turned out to be the most frequent one, and 
the most frequently isolated gram-positive bacterium 
was MRSA1,20,29. VAP etiology uncovered within the 
frame of our study was pretty much the same. Also, in 
our study Staphylococcus aureus was the most frequent-
ly isolated species in tracheotomized patients, ac-
counting for 38% (24/63) of ETA isolates. According 
to Park et al., one of the risk factors for VAP caused 
by Staphylococcus aureus is neurosurgical procedure as 
a reason for ICU admission, and our study group of 
tracheotomized patients included 66% (51/77) of neu-
rosurgical patients33. 
Conclusion
Although many studies have shown tracheotomy 
to be a major risk factor for VAP development13-19, 
our study results do not support that claim. Our data 
suggest that lower VAP incidences are to be expected 
in tracheotomized patients. According to our data, 
tracheotomized VAP patients have reduced mortality 
rates regardless of the tracheotomy being performed 
before or after VAP onset. Also, the present study in-
dicated tracheotomy to be associated with a reduced 
duration of mechanical ventilation after VAP onset, 
but only if patients were tracheotomized at the mo-
ment of VAP onset. 
Our study had some limitations in terms of its ret-
rospective and observational design, the heterogene-
ity of reasons for ICU admission (general surgical and 
neurosurgical grounds), a single ICU coverage, and a 
small sample size, especially when it comes to the “T 
before VAP” group.
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Sažetak
UTJECAJ TRAHEOTOMIJE NA KLINIČKI TIJEK VENTILACIJSKE PNEUMONIJE
T. Magdić Turković, A. Lukić, I. Pažur, O. Ožegić i M. Obraz
Ventilacijska pneumonija (ventilator-associated pneumonia, VAP) je jedna od najčešćih infekcija među bolesnicima u 
jedinicama intenzivnog liječenja (JIL). Cilj ovoga istraživanja je bio utvrditi utjecaj traheotomije na klinički tijek VAP-a. 
Istraživanje je provedeno u 15-krevetnoj Jedinici intenzivnog liječenja Odjela za anesteziologiju, reanimatologiju i inten-
zivno liječenje u Kliničkom bolničkom centru “Sestre milosrdnice”, Zagreb, Hrvatska. Svi bolesnici u kojih se razvila 
VAP tijekom navedenog razdoblja bili su uključeni u istraživanje. U bolesnika s VAP koji nisu traheotomirani (T) tijekom 
njihovog boravka u JIL-u smrtnost je bila otprilike dva puta veća u usporedbi s bolesnicima koji su traheotomirani prije 
ili nakon razvoja VAP (crude risk ratio 1,83, 95% confidence interval (CI) 1,15-2,91, p=0,01; crude odds ratio 3,47, 95% CI 
1,52-7,94; p=0,003). Među preživjelim bolesnicima trajanje mehaničke ventilacije prije razvoja VAP je bilo duže u skupini 
“T prije VAP” u usporedbi sa skupinom “bez T prije VAP” (8, 6-10 prema 3, 2-5; p<0,001), ali je broj dana mehaničke 
ventilacije nakon razvoja VAP bio kraći u bolesnika skupine “T prije VAP” u usporedbi s onima skupine “bez T prije VAP” 
(0, 0-1 prema 4, 3-9; p<0,001). Trajanje mehaničke ventilacije nakon razvoja VAP u skupini “T nakon VAP” je bilo duže u 
usporedbi sa skupinom “T prije VAP” (4, 3-12 prema 0, 0-1; p<0,001). Ovo istraživanje je ukazalo na to da je traheotomija 
povezana s kraćim trajanjem mehaničke ventilacije nakon pojave VAP, ali samo ako su bolesnici u trenutku pojave VAP 
traheotomirani. 
Ključne riječi: Intenzivna skrb; Traheotomija; Pneumonija, ventilacijska; Prognoza; Preživljavanje, analiza; Ishod liječenja
